Search
for
Sort by
Research 151–180 of 1000+
- Diagnosis and treatments of hirsutism: where are we?
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
- Telogen Effluvium
- Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
- Platelet-Rich Plasma as a Treatment for Androgenetic Alopecia
- Expanding the therapeutic landscape of minoxidil for androgenetic alopecia: topical, oral and sublingual formulations
- Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024
- Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise
- Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
- Telogen Effluvium
- Treatment of Alopecia in Children
- Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata
- Exploiting Recent Trends in the Treatment of Androgenic Alopecia through Topical Nanocarriers of Minoxidil
- SERUM VITAMIN D3 LEVELS IN PATIENTS WITH TELOGEN EFFLUVIUM IN DUHOK GOVERNORATE
- Androgenetic alopecia: new insights into the pathogenesis and mechanism of hair loss
- Clinicopathologic Characteristics and Response to Treatment of Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors
- Faculty Opinions recommendation of Distinguishing androgenetic alopecia from chronic telogen effluvium when associated in the same patient: a simple noninvasive method.
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- The Alopecia Areata Severity and Morbidity Index (ASAMI) Study
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Process Optimization and Efficacy Assessment of Standardized PRP for Tendinopathies in Sports Medicine: Retrospective Study of Clinical Files and GMP Manufacturing Records in a Swiss University Hospital
- Health‐related quality of life of adult and adolescent patients living with alopecia areata in Australia
- Alopecia Areata–Specific Patient-Reported Outcome Measures
- Psychosocial and Occupational Burden on Caregivers of Adolescents With Alopecia Areata in Australia
- Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss
- Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
- Med Check
- Hair presentation test
- Systemic minoxidil for hair disorders in pediatric patients: a safety and tolerability review
- Faculty Opinions recommendation of Therapeutic implications of topical cetirizine 1% in treatment of male androgenetic alopecia: A case-controlled study.